Please assess the completion status of the following clinical trial:

Trial Title: Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of VOD, defined by jaundice (bilirubin \>/= 2 mg/dL) and at least 2 of the following clinical findings, by Day+21 post stem cell transplant: ascites; weight gain \>/= 5% above baseline weight; hepatomegaly.~* Severe VOD, defined as VOD with multi-organ failure, i.e., presence of one or both of the following, by Day+28 post stem cell transplant: renal or pulmonary dysfunction.~* Provide voluntary written informed consent.~Exclusion Criteria:~* Pre-existing (prior to SCT) cirrhosis~* An alternative diagnosis for weight gain, ascites and jaundice~* Graft-versus-host disease (GVHD) grade B or higher involving liver or gut or grade C or higher involving skin~* Prior solid organ transplant~* Dependent on dialysis prior to and/or at the time of SCT~* Dependent on oxygen supplementation prior to SCT~* Significant acute bleeding or hemodynamic instability~* Requirement for the use of any medications that increase risk of hemorrhage will be excluded from the treatment group

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Defibrotide (Type: EXPERIMENTAL): Defibrotide treatment
- Historical Control (Type: NO_INTERVENTION): Historical control group

Based on this trial design, predict the completion outcome and termination type (if applicable).